| 1. |
- Backman, L, et al.
(författare)
-
Semantic Memory Functioning Across the Adult Life Span
- 1996
-
Ingår i: EUROPEAN PSYCHOLOGIST. - : Hogrefe Publishing Group. - 1016-9040 .- 1878-531X. ; 1:1, s. 27-33
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Using data from the first wave of data collection in the Betula project, this research examined semantic memory performance in adulthood and old age (N = 1000). The Betula project is a 10-year longitudinal study on memory and health that involves participants from 10 age groups: 35, 40, 45, …, and 80 years of age. Results from tests of verbal fluency and vocabulary indicated no performance variation between 35 and 50 years of age, followed by a gradual deterioration with increasing age. In a test of general knowledge, only the two oldest cohorts showed deficits. When educational level was statistically controlled, a different pattern of results was seen: the middle-aged adults performed at the highest level and, with the exception of one fluency test, no age-related deficits were observed before 75 years of age. These results suggest that, although there may be age-related deficits in semantic memory in the general population, education appears to be a more important factor than adult age per se for semantic memory functioning. The data support the view that activation of preexisting memory representations is relatively unaffected by the adult aging process, and demonstrate the pivotal role of cultural factors (e.g., education, verbal experience) in proficient semantic memory functioning.
|
|
| 2. |
- Campieri, M, et al.
(författare)
-
Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group
- 1997
-
Ingår i: Gut. - : BMJ. - 0017-5749 .- 1468-3288. ; 41:2, s. 209-214
-
Tidskriftsartikel (refereegranskat)abstract
- Background—The use of corticosteroids in active Crohn’s disease often becomes limited by side effects. Budesonide is a potent corticosteroid with low systemic bioavailability due to an extensive first pass liver metabolism.Aims—To compare the efficacy and safety of two dosage regimens of budesonide and prednisolone in patients with active Crohn’s disease affecting the ileum and/or the ascending colon.Patients and methods—One hundred and seventy eight patients were randomised to receive budesonide controlled ileal release (CIR) capsules 9 mg once daily or 4.5 mg twice daily, or prednisolone tablets 40 mg once daily. The treatment period was 12 weeks. The primary efficacy variable was clinical remission, defined as a Crohn’s Disease Activity Index (CDAI) of 150 or less.Results—After eight weeks of treatment, remission occurred in 60% of patients receiving budesonide once daily or prednisolone and in 42% of those receiving budesonide twice daily (p=0.062). The presence of glucocorticoid associated side effects was similar in all groups; however, moon face was more common in the prednisolone group (p=0.0005). The highest frequency of impaired adrenal function, as measured by a short ACTH test, was found in the prednisolone group (p=0.0023).Conclusions—Budesonide CIR, administered at 9 mg once daily or 4.5 mg twice daily, is comparable to prednisolone in inducing remission in active Crohn’s disease. The single dose administration is as promptly effective as prednisolone and represents a simpler and safer therapeutic approach, with a considerable reduction in side effects.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Lynge, E, et al.
(författare)
-
Risk of cancer and exposure to gasoline vapors
- 1997
-
Ingår i: American journal of epidemiology. - : Oxford University Press (OUP). - 0002-9262 .- 1476-6256. ; 145:5, s. 449-458
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
